Filiz Çelebi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Filiz Çelebi has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Gul Alco
Department of Radiation Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey
7 shared publications - Cetin Ordu
Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey
6 shared publications - Alper Ozturk
Biruni Univ, Fac Med, Dept Gen Surg, Istanbul, Turkiye
5 shared publications - Gursel Soybir
Department of Surgery Sisli Memorial Hospital Istanbul Türkiye
5 shared publications - Tomris Duymaz
Department of Physiotherapy and Rehabilitation, İstanbul Bilgi University Faculty of Health Sciences, İstanbul, Turkey
5 shared publications - Vahit Ozmen
Department of Surgery, Head of Breast Surgery Unit Istanbul Florence Nightingale Hospital Istanbul Türkiye
5 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3616
Artificial Intelligence–Assisted ACR TI-RADS and Bethesda-like Risk Prediction for Indeterminate Thyroid Nodules: A Retrospective Proof-of-Concept Evaluation
Background/Objectives: Cytologically indeterminate thyroid nodules (Bethesda III–IV) remain a diagnostic challenge. We evaluated the TRAICK (version 1.9.4; TRAICK, Istanbul, Türkiye) artificial intelligence (AI) system, which generates an American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) category and an imaging-derived Bethesda-like risk category from gray-scale ultrasound images. Methods: This retrospective proof-of-concept study included 52 surgically resected nodules with Bethesda III (n = 29) or IV (n = 23) cytology, with histopathology of the index nodule as the reference standard. The two TRAICK outputs were analyzed separately, and the ACR TI-RADS output was compared with two radiologists using the McNemar and DeLong tests. Results: Twenty-three nodules (44.2%) were malignant on index-nodule histopathology. The TRAICK ACR TI-RADS output had an accuracy of 71.2% (95% CI 57.7–81.7) and an area under the ROC curve (AUC) of 0.762 (0.640–0.884). Its AUC did not differ significantly from that of Radiologist 1 (0.762 vs. 0.777, p = 0.783); specificity was higher (65.5% vs. 37.9%, p = 0.021), whereas sensitivity was lower without a statistically significant difference (78.3% vs. 91.3%, p = 0.250). Compared with Radiologist 2, the TRAICK ACR TI-RADS output had higher accuracy (71.2% vs. 51.9%, p = 0.013), specificity (65.5% vs. 24.1%, p < 0.001), and AUC (0.762 vs. 0.629, p = 0.042). The Bethesda-like output had an AUC of 0.822 (0.707–0.938), with a sensitivity of 60.9% and specificity of 86.2% at the V–VI threshold. In sensitivity analyses, the AUC of the ACR TI-RADS output did not differ significantly from that of Radiologist 1, whereas its AUC advantage over Radiologist 2 was not statistically significant when low-risk neoplasms were classified as malignant. Conclusions: In this small, selected surgical cohort, the TRAICK ACR TI-RADS output showed discrimination that did not differ significantly from that of the more accurate of two experienced radiologists, with higher specificity, and its Bethesda-like output showed promising discrimination. These findings support further study of TRAICK as a complementary aid for preoperative decision-making; independent prospective validation is needed.
- 2 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3616
Open AccessArtificial Intelligence–Assisted ACR TI-RADS and Bethesda-like Risk Prediction for Indeterminate Thyroid Nodules: A Retrospective Proof-of-Concept Evaluation
Background/Objectives: Cytologically indeterminate thyroid nodules (Bethesda III–IV) remain a diagnostic challenge. We evaluated the TRAICK (version 1.9.4; TRAICK, Istanbul, Türkiye) artificial intelligence (AI) system, which generates an American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) category and an imaging-derived Bethesda-like risk category from gray-scale ultrasound images. Methods: This retrospective proof-of-concept study included 52 surgically resected nodules with Bethesda III (n = 29) or IV (n = 23) cytology, with histopathology of the index nodule as the reference standard. The two TRAICK outputs were analyzed separately, and the ACR TI-RADS output was compared with two radiologists using the McNemar and DeLong tests. Results: Twenty-three nodules (44.2%) were malignant on index-nodule histopathology. The TRAICK ACR TI-RADS output had an accuracy of 71.2% (95% CI 57.7–81.7) and an area under the ROC curve (AUC) of 0.762 (0.640–0.884). Its AUC did not differ significantly from that of Radiologist 1 (0.762 vs. 0.777, p = 0.783); specificity was higher (65.5% vs. 37.9%, p = 0.021), whereas sensitivity was lower without a statistically significant difference (78.3% vs. 91.3%, p = 0.250). Compared with Radiologist 2, the TRAICK ACR TI-RADS output had higher accuracy (71.2% vs. 51.9%, p = 0.013), specificity (65.5% vs. 24.1%, p < 0.001), and AUC (0.762 vs. 0.629, p = 0.042). The Bethesda-like output had an AUC of 0.822 (0.707–0.938), with a sensitivity of 60.9% and specificity of 86.2% at the V–VI threshold. In sensitivity analyses, the AUC of the ACR TI-RADS output did not differ significantly from that of Radiologist 1, whereas its AUC advantage over Radiologist 2 was not statistically significant when low-risk neoplasms were classified as malignant. Conclusions: In this small, selected surgical cohort, the TRAICK ACR TI-RADS output showed discrimination that did not differ significantly from that of the more accurate of two experienced radiologists, with higher specificity, and its Bethesda-like output showed promising discrimination. These findings support further study of TRAICK as a complementary aid for preoperative decision-making; independent prospective validation is needed.
- Open Access
- 14 April 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (6) , 1396-1405
Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial
Introduction: Achieving a pCR serves as a biomarker indicating enhanced overall survival for breast cancer patients undergoing NST. Vitamin D enhances the antitumor effect of chemotherapeutics as demonstrated in cancer cells and animal models. In this prospective randomized clinical study, we aim to investigate the effect of oral vitamin D supplementation during neoadjuvant systemic therapy (NST) on pathologic complete response (pCR). Methods: Between June 2019 and June 2023, an oral form of 50,000 IU vitamin D3 (cholecalciferol) replacement was administered once a week during NST for the study group. Results: There were 114 (50.2%) cases in the study group and 113 (49.8%) in the control group (totally 227 cases). Factors that positively influenced pCR were higher clinical T stage, higher AJCC clinical stage, Estrogen receptor negativity, progesterone receptor negativity, human epidermal growth factor receptor 2 positivity, high Ki‐67 expression (≥ 20%), hormone negative molecular subtypes, and vitamin D intake in univariate analysis. In the multivariate analysis, factors significantly affecting pCR were vitamin D intake (OR: 2.33, 95% CI 1.20–4.53; p = 0.013), hormone receptor negativity (OR: 2.22, 95% CI 1.11–4.43; p = 0.024), and Ki‐67 ≥ 20% (OR: 3.27, 95% CI 1.03–10.34; p = 0.044). Conclusions: This is the first and only study to compare the effect of oral vitamin D supplementation on pCR during NST. Vitamin D supplementation during NST has a significant effect on pCR in breast cancer patients. Although this effect is not significant for axillary pCR, there is an almost significant correlation. Trial Registration: ClinicalTrials.gov (Identifier: NCT03986268)
- 14 April 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (6) , 1396-1405
Open AccessVitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial
Introduction: Achieving a pCR serves as a biomarker indicating enhanced overall survival for breast cancer patients undergoing NST. Vitamin D enhances the antitumor effect of chemotherapeutics as demonstrated in cancer cells and animal models. In this prospective randomized clinical study, we aim to investigate the effect of oral vitamin D supplementation during neoadjuvant systemic therapy (NST) on pathologic complete response (pCR). Methods: Between June 2019 and June 2023, an oral form of 50,000 IU vitamin D3 (cholecalciferol) replacement was administered once a week during NST for the study group. Results: There were 114 (50.2%) cases in the study group and 113 (49.8%) in the control group (totally 227 cases). Factors that positively influenced pCR were higher clinical T stage, higher AJCC clinical stage, Estrogen receptor negativity, progesterone receptor negativity, human epidermal growth factor receptor 2 positivity, high Ki‐67 expression (≥ 20%), hormone negative molecular subtypes, and vitamin D intake in univariate analysis. In the multivariate analysis, factors significantly affecting pCR were vitamin D intake (OR: 2.33, 95% CI 1.20–4.53; p = 0.013), hormone receptor negativity (OR: 2.22, 95% CI 1.11–4.43; p = 0.024), and Ki‐67 ≥ 20% (OR: 3.27, 95% CI 1.03–10.34; p = 0.044). Conclusions: This is the first and only study to compare the effect of oral vitamin D supplementation on pCR during NST. Vitamin D supplementation during NST has a significant effect on pCR in breast cancer patients. Although this effect is not significant for axillary pCR, there is an almost significant correlation. Trial Registration: ClinicalTrials.gov (Identifier: NCT03986268)
- Open Access
- 2 January 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (1) , 33-39
Artificial Intelligence in Diagnostic Breast Ultrasound: A Comparative Analysis of Decision Support Among Radiologists With Various Levels of Expertise
Artificial Intelligence in Diagnostic Breast Ultrasound: A Comparative Analysis of Decision Support Among Radiologists With Various Levels of Expertise - European Journal of Breast Health
- 2 January 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (1) , 33-39
Open AccessArtificial Intelligence in Diagnostic Breast Ultrasound: A Comparative Analysis of Decision Support Among Radiologists With Various Levels of Expertise
Artificial Intelligence in Diagnostic Breast Ultrasound: A Comparative Analysis of Decision Support Among Radiologists With Various Levels of Expertise - European Journal of Breast Health
- Open Access
- 2 January 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (1) , 40-45
Evaluation of Long-Term Lymphedema Rate in Patients With Subclinical Lymphedema Diagnosed in the Preoperative Period via Bioimpedance
Undefined - European Journal of Breast Health
- 2 January 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (1) , 40-45
Open AccessEvaluation of Long-Term Lymphedema Rate in Patients With Subclinical Lymphedema Diagnosed in the Preoperative Period via Bioimpedance
Undefined - European Journal of Breast Health
- 1 April 2024
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 20 (2) , 117-121
The Relationship of Pathological Response and Visceral Muscle and Fat Volume in Women With Breast Cancer Who Received Neoadjuvant Chemotherapy
Objective: Differences in individual muscle/fat volumes may change the effectiveness of chemotherapy. In this study, the relationship between trunkal muscle and fat volume and body mass index (BMI) obtained before receiving neoadjuvant chemotherapy (NCT) in patients with breast cancer and complete pathological response (pCR) was investigated. Materials and Methods: The volumes of psoas, abdominal and paraspinal muscles, and trunkal subcutaneous and visceral fat were calculated using CoreSlicer AI 2.0 opensource program from the F-18 fluorodeoxyglucose positron emission tomography/computed tomography (CT) and CT images before NCT and postoperative pCR rates to NCT were recorded. Muscle/fat volumes and BMI prior to NCT were compared in terms of pathological pCR rates. Patients were followed up regularly for recurrence and survival. Results: Ninety-three patients were included with median (range) values for age, BMI, and body weights of 48 (28-72) years, 27 (16.8-51.6) kg/m(2), and 71.94 (43-137) kg, respectively. The median follow-up time was 18.6 (6.7-59.6) months. No significant correlation was found between total muscle or fat volumes of patients with and without pCR. BMI [26.2 (16.8-51.6) kg/m(2) vs. 24.6 (20.3-34.3) kg/m(2), p = 0.03] and pCR rates in patients with low rightpsoas muscle volume [11.74 (7.03-18.51) vs. 10.2 (6.71-13.36), p = 0.025] were significantly greater. A significant relationship was found between right psoas muscle volume and disease-free survival (DFS) (11.74 cm(3) (7.03-18.51) vs. 10.2 cm(3) (6.71-13.36), p = 0.025). However, no significant relationship was detected between total muscle-fat volume, BMI and overall survival and DFS (p>0.05). Conclusion: This is the first published study investigating the relationship between the pCR ratio and body muscle and fat volume measured by CoreSlicer AI 2.0 in patients with breast cancer who received NCT. No correlation was found between the pCR ratio and total muscle plus fat volume. However, these results need to be validated with larger patient series.
- 1 April 2024
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 20 (2) , 117-121
The Relationship of Pathological Response and Visceral Muscle and Fat Volume in Women With Breast Cancer Who Received Neoadjuvant Chemotherapy
Objective: Differences in individual muscle/fat volumes may change the effectiveness of chemotherapy. In this study, the relationship between trunkal muscle and fat volume and body mass index (BMI) obtained before receiving neoadjuvant chemotherapy (NCT) in patients with breast cancer and complete pathological response (pCR) was investigated. Materials and Methods: The volumes of psoas, abdominal and paraspinal muscles, and trunkal subcutaneous and visceral fat were calculated using CoreSlicer AI 2.0 opensource program from the F-18 fluorodeoxyglucose positron emission tomography/computed tomography (CT) and CT images before NCT and postoperative pCR rates to NCT were recorded. Muscle/fat volumes and BMI prior to NCT were compared in terms of pathological pCR rates. Patients were followed up regularly for recurrence and survival. Results: Ninety-three patients were included with median (range) values for age, BMI, and body weights of 48 (28-72) years, 27 (16.8-51.6) kg/m(2), and 71.94 (43-137) kg, respectively. The median follow-up time was 18.6 (6.7-59.6) months. No significant correlation was found between total muscle or fat volumes of patients with and without pCR. BMI [26.2 (16.8-51.6) kg/m(2) vs. 24.6 (20.3-34.3) kg/m(2), p = 0.03] and pCR rates in patients with low rightpsoas muscle volume [11.74 (7.03-18.51) vs. 10.2 (6.71-13.36), p = 0.025] were significantly greater. A significant relationship was found between right psoas muscle volume and disease-free survival (DFS) (11.74 cm(3) (7.03-18.51) vs. 10.2 cm(3) (6.71-13.36), p = 0.025). However, no significant relationship was detected between total muscle-fat volume, BMI and overall survival and DFS (p>0.05). Conclusion: This is the first published study investigating the relationship between the pCR ratio and body muscle and fat volume measured by CoreSlicer AI 2.0 in patients with breast cancer who received NCT. No correlation was found between the pCR ratio and total muscle plus fat volume. However, these results need to be validated with larger patient series.
- Open Access
- 19 October 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (10) , 9217-9229
Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study
Estradiol (E2), a follicle-stimulating hormone (FSH), AMH, and inhibin B levels, along with AFC and MOV, are used to determine ovarian reserve in pre-menopausal women. Studies have shown that AMH levels are more sensitive than those of E2, FSH, and inhibin B and that AFC and MOV can be used to evaluate ovarian reserve. AMH, AFC, and MOV measurements were performed before and after adjuvant SC in 3-month periods for one year. Patients were classified as experiencing chemotherapy-induced amenorrhea (CIA) if they did not have menstrual cycles for a period of six months or longer following the conclusion of their chemotherapy treatment. We aimed to evaluate the factors affecting chemotherapy-induced amenorrhea in breast cancer patients treated with adjuvant chemotherapy and the performance of baseline measurements of AMH, AFC, and MOV to predict chemotherapy-induced amenorrhea. The effects of different chemotherapy regimens on the AMH level, AFC, and MOV in CIA patients were investigated. Seventy-one patients were eligible for this study, and the median age was 38 years (range: 23–45). The median follow-up was 37 months (range: 20–51), and CIA developed in 62% of the patients. The AMH level and AFC were significantly decreased one year after SC (p < 0.0001), whereas MOV was not (p = 0.507). AMH levels before chemotherapy (median: 1.520 vs. 0.755, p = 0.001) and at the end of the first year (median: 0.073 vs. 0.010, p = 0.030) and pre-treatment AFC (median: 12 vs. 4.50, p = 0.026) were lower in patients with CIA compared to those without CIA. The AMH levels before SC were the most valuable and earliest factor for predicting CIA development. In addition, there was no difference between the chemotherapy regimens (including or not including taxane) in terms of CIA development.
- 19 October 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (10) , 9217-9229
Open AccessEvaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study
Estradiol (E2), a follicle-stimulating hormone (FSH), AMH, and inhibin B levels, along with AFC and MOV, are used to determine ovarian reserve in pre-menopausal women. Studies have shown that AMH levels are more sensitive than those of E2, FSH, and inhibin B and that AFC and MOV can be used to evaluate ovarian reserve. AMH, AFC, and MOV measurements were performed before and after adjuvant SC in 3-month periods for one year. Patients were classified as experiencing chemotherapy-induced amenorrhea (CIA) if they did not have menstrual cycles for a period of six months or longer following the conclusion of their chemotherapy treatment. We aimed to evaluate the factors affecting chemotherapy-induced amenorrhea in breast cancer patients treated with adjuvant chemotherapy and the performance of baseline measurements of AMH, AFC, and MOV to predict chemotherapy-induced amenorrhea. The effects of different chemotherapy regimens on the AMH level, AFC, and MOV in CIA patients were investigated. Seventy-one patients were eligible for this study, and the median age was 38 years (range: 23–45). The median follow-up was 37 months (range: 20–51), and CIA developed in 62% of the patients. The AMH level and AFC were significantly decreased one year after SC (p < 0.0001), whereas MOV was not (p = 0.507). AMH levels before chemotherapy (median: 1.520 vs. 0.755, p = 0.001) and at the end of the first year (median: 0.073 vs. 0.010, p = 0.030) and pre-treatment AFC (median: 12 vs. 4.50, p = 0.026) were lower in patients with CIA compared to those without CIA. The AMH levels before SC were the most valuable and earliest factor for predicting CIA development. In addition, there was no difference between the chemotherapy regimens (including or not including taxane) in terms of CIA development.
- 26 August 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (29) , 3289-3298
The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer
Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: One hundred fifteen pa... Plain language summary New studies have shown that the tumor microenvironment is critical in tumor behavior. Immune cells surrounding tumor cells are the main components of the tumor microenvironme...
- 26 August 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (29) , 3289-3298
The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer
Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: One hundred fifteen pa... Plain language summary New studies have shown that the tumor microenvironment is critical in tumor behavior. Immune cells surrounding tumor cells are the main components of the tumor microenvironme...
- 26 May 2021
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 6 (2) , 118-124
Evaluation of the Morphometric Measurements of Main Mediastinal Vascular Structures with Multi-detector Computed Tomography in Healthy Children
- 26 May 2021
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 6 (2) , 118-124
Evaluation of the Morphometric Measurements of Main Mediastinal Vascular Structures with Multi-detector Computed Tomography in Healthy Children
- 1 February 2021
- Published by Elsevier in Academic Radiology
- Vol. 28 (2) , 189-198
The Role of 18F-FDG PET/MRI in the Assessment of Primary Intrahepatic Neoplasms
- 1 February 2021
- Published by Elsevier in Academic Radiology
- Vol. 28 (2) , 189-198
The Role of 18F-FDG PET/MRI in the Assessment of Primary Intrahepatic Neoplasms
- 21 August 2020
- Published by Springer Nature in Neuroradiology
- Vol. 63 (3) , 331-342
Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma
Purpose With conventional MRI, it is often difficult to effectively differentiate between contrast-enhancing brain tumors, including primary central nervous system lymphoma (PCNSL), high-grade glioma (HGG), and metastasis. This study aimed to assess the discrimination ability of the parameters obtained from DWI and the percentage signal recovery- (PSR-) optimized protocol of DSC-MRI between these three tumor types at an initial step. Methods DSC-MRI using a PSR-optimized protocol (TR/TE = 1500/30 ms, flip angle = 90°, no preload) and DWI of 99 solitary enhancing tumors (60 HGGs, 24 metastases, 15 PCNSLs) were retrospectively assessed before treatment. rCBV, PSR, ADC in the tumor core and rCBV, and ADC in peritumoral edema were measured. The differences were evaluated using one-way ANOVA, and the diagnostic performance was evaluated using ROC curve analysis. Results PSR in the tumor core showed the best discriminating performance in differentiating these three tumor types with AUC values of 0.979 for PCNSL vs. others and 0.947 for HGG vs. metastasis. The ADC was only helpful in the tumor core and distinguishing PCNSLs from others (AUC = 0.897). Conclusion Different from CBV-optimized protocols (preload, intermediate FA), PSR derived from the PSR-optimized protocol seems to be the most important parameter in the differentiation of HGGs, metastases, and PCNSLs at initial diagnosis. This property makes PSR remarkable and carries the need for comprehensive DSC-MRI protocols, which provides PSR sensitivity and CBV accuracy together, such as the preload use of the PSR-optimized protocol before the CBV-optimized protocol.
- 21 August 2020
- Published by Springer Nature in Neuroradiology
- Vol. 63 (3) , 331-342
Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma
Purpose With conventional MRI, it is often difficult to effectively differentiate between contrast-enhancing brain tumors, including primary central nervous system lymphoma (PCNSL), high-grade glioma (HGG), and metastasis. This study aimed to assess the discrimination ability of the parameters obtained from DWI and the percentage signal recovery- (PSR-) optimized protocol of DSC-MRI between these three tumor types at an initial step. Methods DSC-MRI using a PSR-optimized protocol (TR/TE = 1500/30 ms, flip angle = 90°, no preload) and DWI of 99 solitary enhancing tumors (60 HGGs, 24 metastases, 15 PCNSLs) were retrospectively assessed before treatment. rCBV, PSR, ADC in the tumor core and rCBV, and ADC in peritumoral edema were measured. The differences were evaluated using one-way ANOVA, and the diagnostic performance was evaluated using ROC curve analysis. Results PSR in the tumor core showed the best discriminating performance in differentiating these three tumor types with AUC values of 0.979 for PCNSL vs. others and 0.947 for HGG vs. metastasis. The ADC was only helpful in the tumor core and distinguishing PCNSLs from others (AUC = 0.897). Conclusion Different from CBV-optimized protocols (preload, intermediate FA), PSR derived from the PSR-optimized protocol seems to be the most important parameter in the differentiation of HGGs, metastases, and PCNSLs at initial diagnosis. This property makes PSR remarkable and carries the need for comprehensive DSC-MRI protocols, which provides PSR sensitivity and CBV accuracy together, such as the preload use of the PSR-optimized protocol before the CBV-optimized protocol.